Luke headshot

Luke Evnin, Ph.D.

Luke Evnin is managing director of MPM Capital, a venture firm dedicated to life sciences investing. Dr. Evnin co-founded MPM’s asset management business in 1997 to launch MPM’s first venture fund and established the San Francisco office for the firm in 1999. Previously, Dr. Evnin was at Accel Partners for over seven years including four as a General Partner.  At Accel Partners, he was involved in biopharmaceutical, medical device and healthcare service companies for Accel’s funds III, IV and V. Dr. Evnin earned his Ph.D. in the Department of Biochemistry at the University of California-San Francisco, and he received his A.B. in Molecular Biology magna cum laude from Princeton University. He serves on the External Advisory Board for QB3, the Advisory Board for Mission Bay Capital (the internal venture investment vehicle for QB3), the External Advisory Board for the Lewis Sigler Institute of Quantitative Genomics at Princeton, and is the Chairman of the Scleroderma Research Foundation. 

Lori Kunkel 41

Lori Kunkel, M.D.

Dr. Lori Anne Kunkel has held executive positions in a variety of companies that have provided her extensive experience in developing and commercializing oncologic/immunologic therapies. Her areas of responsibilities have included clinical, regulatory, medical affairs and licensing. She has participated as a strategic clinical advisor and consultant to several corporations, as well as a consultant for Boston and Bay area Venture Capital firms. She is currently Chief Medical Officer (CMO) at Loxo, Oncology; prior to that she was the CMO at Pharmacyclics. Inc., where she was instrumental in achieving breakthrough designations for the lead product, ibrutinib; and filed the NDA that led to approval. She served as CMO at Proteolix (acquired by Onyx), and at Syndax and ACT. Dr. Kunkel has led numerous agents through EU and US strategic regulatory meetings, INDs, Orphan Drug designations, Special Protocol Assessments, and has filed both NDAs and BLAs. Dr. Kunkel spent ten years in academic/clinical medicine and served as a faculty member in the Division of Hematology/Oncology Bone Marrow transplant unit at University of California, Los Angeles prior to joining the international biotechnology industry in 1995. Dr. Kunkel holds a Bachelor of Arts in Biology from University of California, San Diego; a medical degree from University of Southern California. She has held board certification in Internal Medicine, Hematology and Oncology.

Jeanmarie Guenot

Jeanmarie Guenot, Ph.D.

President and CEO

Jeanmarie Guenot, Ph.D. has over 20 years of experience in the pharmaceutical and biotechnology industry. She has worked with all stages of companies, both public and private, in pharmaceutical R&D, corporate & commercial development, business development, project & alliance management and venture capital. She has significant expertise and interest in building or rebuilding companies and is currently the President & CEO of Amphivena Therapeutics, Inc., a company that is developing innovative bifunctional antibody therapies for hematologic malignancies.

Prior to her current role, Dr. Guenot founded, built and ran SKS Ocular, a start-up ophthalmic company incubator, focused on dry AMD, sustained release ocular drug delivery technologies and therapeutics for glaucoma, macular degeneration and ocular inflammation.  She was a business advisor for Hoffmann-La Roche in Basel and Shanghai, and she was Vice President of Corporate & Business Development at PDL BioPharma, where she led licensing, mergers and acquisitions and alliance management for PDL’s R&D and commercial product portfolios.  She led and negotiated the Biogen Idec-PDL 50:50 co-development and co-commercialization strategic collaboration, which involved three Phase 2 cancer and autoimmune disease drug candidates.  This $800 M transaction included a $100 M equity investment in PDL and a therapeutic candidate with indications split between Biogen Idec/PDL and Hoffmann-La Roche.   She also licensed the ophthalmic indication for the oncology drug to Ophthotech.  She has portfolio, project and alliance management experience in the areas of oncology, cardiovascular diseases, autoimmune diseases, neurology and ophthalmic diseases.

Dr. Guenot started her business career at Atlas Venture, where she managed venture capital investments and built life science companies.  She started her scientific career as a principal scientist in Preclinical R&D at Hoffmann-La Roche, discovering and developing drugs for metabolic diseases, inflammation, autoimmune diseases and oncology.  Dr. Guenot trained in physical and medicinal chemistry, with a focus in quantum mechanical and semi-empirical methods for molecular dynamics, protein structure prediction, X-ray and NMR refinement and drug design.  She earned her Ph.D. from the University of California, San Francisco and her MBA from The Wharton School at the University of Pennsylvania.

Adi Hoess

Adi Hoess, Ph.D.

Dr Hoess joined Affimed in October 2010 as Chief Commercial Officer and since September 2011 leads the company as CEO. He has more than 18 years professional experience with an extensive background in general management, business development, product commercialization, fund raising and M&A. Prior to Affimed, Dr. Hoess was Chief Commercial Officer at Jerini AG and CEO of Jenowis AG. At Jerini AG he was responsible for BD and the market introduction of Firazyr. He also played a major role in the M&A process of Jerini AG with Shire. From 2000 – 2002 Dr. Hoess was General Manager and VP of the Molecular Medicine Division at Carl-Zeiss in Jena. Dr. Hoess began his professional career in 1993 at MorphoSys as scientist. In 1997 he became Director of BD and in 1999, VP of Licensing and BD.

Dr. Hoess received his PhD in chemistry and biochemistry from the University of Munich in 1991, and he also received an M.D. from the Technical University (TU) of Munich in 1997. From 1991 until 1993 Dr Hoess work as a post doc at the Dana-Faber Cancer Institute at the Harvard Medical School in Boston, USA.

FF

Florian Fischer, Ph. D.

Dr. Fischer joined Affimed in 2005 as CFO on a part-time basis. Since September 2014, Dr. Fischer is fulltime employed by Affimed. He has a strong track record in various Biotech/MedTech executive positions, as lead advisor in a variety of transactions and financings in the life sciences and healthcare sector.

Dr. Fischer is founder of MedVenture Partners – a corporate finance and strategy advisory company focusing on the life sciences and healthcare industry. Dr. Fischer was Chief Financial Officer of Activaero GmbH from 2002 until 2011 and responsible for corporate development until the acquisition by Vectura in 2014. He also served as Chief Financial Officer of Vivendy Ltd. from 2008 until 2013 and as managing director of AbCheck in 2009.

Prior to founding MedVenture Partners, Dr. Fischer worked with KPMG for more than six years until 2002, where he was responsible for biotech and healthcare assignments. Before joining KPMG, he worked for Deutsche Bank AG. Dr. Fischer is also a Director of Amphivena.

He holds a graduate degree in business administration from Humboldt University, Berlin and a Ph.D. in public health from the University of Bielefeld.